Tom Winnifrith Bearcast: is my old chum Paul Atherley suffering from Islingtonitis, Guardian reading derangement syndrome?
Superdry – shares up on Q1 “better than our initial expectations”… but what does that mean financially?...
The AA & oh-so-clever hedge fund-style shareholders v. oh-so-clever private equity potential business purchasers...
Hello, Share Prompters. A medical venture I’ve invested in for years and which has usually disappointed is Feedback plc (FDBK). It always appears to me to have huge potential that doesn't seem to have been followed through. Perhaps the company needs more marketing skills. Any road up, it's just had some good news that the share price seems yet to have fully reflected...
Hello, Share Tweakers. It’s with some unease that I suggest you take a look at today’s choice. That’s because Tom has said that he doesn't rate it. And only a fool disregards his astute analysis. But I am sometimes a momentum player, and the company I have in mind could turn out to be a short-term winner...
Writing last week on Feedback plc (FDBK), I concluded with the combination of the noted financials, Bleepa still in development (i.e. very much yet to be “revolutionising clinical messaging”!) and a market cap of sub £5 million, meaning it at best looking like discounted placing ahoy, currently natch avoid / sell. Now “Proposed placing and subscription to raise £2m”…
A “Statement re Online Commentary” from Feedback plc (FDBK) which “confirms that, in order to develop BleepaTM, the company's clinical messaging product, it is currently working on completing a placing of new shares”…
To be clear, I don’t believe Malcolm has ripped off shareholders in an investment trust he manages by stuffing it full of unquoted stocks to save his bacon elsewhere; however, he does seem to have picked up a few of the “star fund manager’s” bad habits when it comes to a stock, namely Feedback (FDBK).
Hello, Shares Lovelies. It’s time to revisit a favourite penny share of mine. Though it’s not exactly repaid my loyalty in the last year. Nevertheless, I feel that, given its potential and support in 40 countries, the present lowly share price is unfair.
Hello, Share Purloiners. There was a welter of off-stage discussion at the last mouth-watering UK Investor Show on April 1st about Feedback (FDBK). It’s another of those AIM-listed medical pioneers, looking to develop new life-saving techniques.
Hello Share Bottlers. Yesterday I took a look at Avacta (AVCT). Now I bring to your notice another medical pioneer, Feedback (FDBK).
Hello Share Rattlers. Quite a few of my friends face a grim Christmas. They are undergoing radio and chemo treatment for cancer. Is it me, or is the number of cases growing even faster than normal?
Hello Share Folk. I’m going to the hospital today to see about my prostate gland. I started the routine tests a few years ago and have been under the eye of a brilliant consultant ever since. There’s a lot of debate of whether we should have these tests done, as it causes a lot of anxiety and their reliability is not always that great. On the whole I would suggest you do have them done, if you’re of a certain age. But what do I know?
In some ways it feels as though the latest call on Feedback is somewhat late in the day, particularly in the wake of the initial spike for the shares to start this week.
Hello Share Bunnies. There was some interesting share movements after all the good news came out for Feedback (FDBK), the minnow capitalised at a mere £5 million.
Hello Share Thrashers. It’s not my custom to return to promising shares I’ve brought to your attention in the recent past. I normally wait at least six months or so - with only a few exceptions.
The present position for shares at Feedback (FDBK) looks to be well backed fundamentally – if you are a fan of rocket science. But as well as this we can bring in the art of technical analysis to attempt to divine where the share price may be heading near term.
Feedback (FDBK) is a company going places. And it’s just gone to another one. This is a compact firm, mostly owned by family and friends, with only a small proportion of ordinary share-shifters like us.
If you want me to analyse a stock for you just drop me a line at email@example.com - Today I look at Bowleven (BLVN), Feedback (FDBK), Union Jack Oil (UJO)
Hello Share Sappers. I beg your indulgence to return to Feedback (FDBK), the company which uses whizzo computers to help diagnose and monitor many types of cancer. As reported previously, this could be a topping investment. Though, as per usual, we should always add a cautionary note about medical pioneers.
Hello Share Swingers. It seems ages ago that I first tipped Feedback (FDBK) the life science company. It was during all the excitement about another medical punt, Advanced Oncotherapy (AVO). I think I said something optimistic along the lines that Feedback could be another Advanced, which is a multi-bagger..
Hello Share Pickers. I told you I usually pick up some decent tips from the UK Investor Show which we were all treated to on Saturday. I’ve now had time to research a few of these diamonds and the first one I’ve bought is Feedback (FDBK).
Search ShareProphets |
Recent Comments |